• Endpoints TScan Therapeutics, Inc. 30 1 2 3 Archival sample <6mo OR fresh biopsy Targets TSC-200 TSC-203 TSC-202 TSC-204 A*02:01A*01:01A*03:01B*07:02C*07:02 TSC-201 A*24:02 TSC-205 HPV16 Target-202 Target-201 PRAME MAGE-A1 Target-205 10+ TCRs in the clinic by the end of 2024 the early stages of building the ImmunoBank 1 2 3 4 5 6 7 8 9 0 20 40 60 80 100 Eligible patients (%) Melanoma -single NSCLC-single TScan Therapeutics, Inc. 33 TCR-T uniquely addresses myeloid leukemias Not addressable by CAR-T therap ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________________________to_____________________________________________________ Commission File Number 001-40603 TSCAN THERAPEUTICS, INC. (Exact name of Regist ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Del ...

Unleash Immunity Corporate Presentation September 2022 1 Disclaimers and forward-looking statements This presentation and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding possible or assumed future results of operations of TScan Therapeutics, Inc. (the "Company", "we", "our" and "us"), expenses and financing needs, business strategies and plans, research and developmen ...

Unleash Immunity Corporate Presentation September 2022 1 Disclaimers and forward-looking statements This presentation and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding possible or assumed future results of operations of TScan Therapeutics, Inc. (the "Company", "we", "our" and "us"), expenses and financing needs, business strategies and plans, research and developmen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 8 ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware ...

TScan Therapeutics, Inc. 1 Unleash Immunity Corporate Presentation March 2022 Disclaimers and forward-looking statements This presentation and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding possible or assumed future results of operations of TScan Therapeutics, Inc. (the "Company", "we", "our" and "us"), expenses and financing needs, business strategies and plans, re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 TSCAN THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organization) 830 Winter Street Waltham, Massachusetts 02451c (Address of principal executive offices) (Zip Code) Delaware 82-5282075 (I.R.S. Employer Identifi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) | Del ...